Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Omnicell Q3 profit rises on connected device demand

By Reuters News


Overview

  • Healthcare technology firm's Q3 revenue declined 1% yr/yr to $308 mln

  • Q3 adjusted net income and adjusted EBITDA rose yr/yr

  • Company raised full-year 2026 non-GAAP EBITDA and EPS guidance


Outlook

  • Omnicell raises full-year 2026 non-GAAP EBITDA guidance to $187 mln-$193 mln

  • Company lifts full-year 2026 non-GAAP EPS outlook to $2.48-$2.56

  • Omnicell tightens full-year 2026 revenue guidance to $1.225 bln-$1.231 bln


Result Drivers

  • CONNECTED DEVICE DEMAND - Co said Q3 results were supported by demand for its connected device portfolio

  • PRODUCT AND SERVICE MARGINS - Co attributed Q3 performance to favorable product and service margins

  • COST MANAGEMENT - Co cited disciplined cost management as a driver of Q3 results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$308 mln

Q3 Adjusted Net Income

$27 mln

Q3 Net Income

$11 mln

Q3 Adjusted EBITDA

$45 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Omnicell Inc is $60.00, about 66.9% above its October 28 closing price of $35.95

  • The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 20 three months ago


Reuters Recommended Reads

  • Oct 28 - GE Healthcare Q3 profit beats estimates on advanced imaging segment

  • Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

  • Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.